Axa
VNDA icon

Axa’s Vanda Pharmaceuticals VNDA Stock Holding History

Axa’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-141,200
Closed -$610K – 1138
2023
Q3 		$610K Buy
+141,200
New +$785K ﹤0.01% 907
2022
Q2 		– Sell
-17,200
Closed -$195K – 1228
2022
Q1 		$195K Buy
+17,200
New +$226K ﹤0.01% 1157
2021
Q4 		– Sell
-23,900
Closed -$410K – 1291
2021
Q3 		$410K Sell
23,900
-2,400
-9% -$42K ﹤0.01% 1093
2021
Q2 		$566K Buy
+26,300
New +$471K ﹤0.01% 1086

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Prudential Financial
Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Axa's VNDA Position: Q4 2023 in Review

Axa sold out of Vanda Pharmaceuticals (VNDA) in Q4 2023, closing a stake of 141,200 shares — an estimated $610K sold.

Axa first reported a position in VNDA in Q2 2021 and held it in 4 quarters. The position peaked at $610K in Q3 2023. 157 funds tracked by Wall St. Rank hold VNDA as of Q4 2023.

  • Axa reported no remaining Vanda Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Axa sold 141,200 Vanda Pharmaceuticals shares in Q4 2023, an estimated $610K.
  • Axa first reported a position in Vanda Pharmaceuticals in Q2 2021 and held it in 4 quarters.
  • Axa's Vanda Pharmaceuticals position peaked at $610K in Q3 2023.
  • 157 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q4 2023.

Based on Axa's 13F filing for Q4 2023, filed 14 Feb 2024.